Test the functional significance of mutations found in your patient’s NGS report and how they respond to drugs

NovellusDx brings actionable information about the mutations found in your patients’ tumor and the response of these mutations to targeted therapies. NovellusDx tests the functional significance of the specific mutations and their interactions in live cells examining how they change the activity level of major cancer signaling pathways and how this is affected by different targeted therapies.

Clinical

Perfect integration into your existing workflow

Easy to use: upload the NGS report and select the drugs to be tested. After in-vitro testing, the resulting activation of the signaling pathways is charted on a personalized interactive map allowing us to explore the treatment options, and providing strong evidence to support the clinical decision.

 

Extensive collaborations and publications

NovellusDx is collaborating with top physicians and diagnostic companies in order to provide additional functional information on their patients’ advanced-cancer. NovellusDx is working with a selected number of physicians in leading medical centers.

If you would like to collaborate, please contact us directly.

FAQ

CAN YOUR ASSAY TEST ANY DRUG?

 

We are is focused on cancer therapy and we cover most targeted therapies (see list below). We are also happy to support clinical investigation of new drugs or indications.

Ado-trastuzumab emtansine (Kadcyla), Afatinib (Gilotrif), Alectinib (Alecensa), Axitinib (Inlyta), Buparlisib, Cabozantinib, Ceritinib (Zykadia), Cetuximab (Erbitux), Cobimetinib (Cotellic), Crizotinib (Xalkori), Dabrafenib (Tafinlar), Dactolisib, Erlotinib (Tarceva), Everolimus (Afinitor), Foretinib, Gefitinib (Iressa), Herceptin (Trastuzumab), Idelalisib (Zydelig), Imatinib (Gleevec), Lapatinib (Tykerb), Lestaurtinib, Necitumumab (Portrazza), Neratinib, Osimertinib (Tagrisso), Pacritinib, Panitumumab (Vectibix), Pazopanib (Votrient), Ponatinib (Iclusig), Regorafenib (Stivarga), Selumetinib, Sorafenib (Nexavar), Sunitinib (Sutent), Temsirolimus (Torisel), Tivantinib, Trametinib (Mekinist), Vemurafenib (Zelboraf)

WHAT ARE VARIANTS OF UNCERTAIN SIGNIFICANCE?

 

A tumor may contain driver mutations, which are known to cause an oncogenic effect, and passenger mutations, which are known not to exert such effect. Alterations which have not been designated as driver or passenger mutations, are called Variants of Uncertain Significance (VUS) and may contribute not only to the development of a tumor, but also to drug resistance.

 

WHAT IS YOUR TURNAROUND TIME?

 

Our turnaround time is about 14 days.

WHAT DO I NEED TO SEND YOU? DO I NEED TO SEND YOU THE BIOPSY?

The only thing we need is the NGS report of the patient. We will synthesize the mutated genes and test them.

WHAT TYPE OF REGULATORY APPROVALS DO YOU HAVE?

 

Our lab is both CMS and CLIA certified. In November 2015, the lab received ISO 13485:2003 for the “development of diagnostic solutions for personalized medicine”. This allows us to serve patients from the US and internationally.